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a b s t r a c t
Benign tumours of the bone are not cancerous and would not metastasise to other regions of the body.
However, they can occur in any part of the skeleton, and can still be dangerous as they may grow and
compress healthy bone tissue. There are several types of benign tumours that can be classiﬁed by the
type of matrix that the tumour cells produce; such as bone, cartilage, ﬁbrous tissue, fat or blood vessel.
Overall, 8 different types can be distinguished: osteochondroma, osteoma, osteoid osteoma, osteoblas-
toma, giant cell tumour, aneurysmal bone cyst, ﬁbrous dysplasia and enchondroma.
The incidence of benign bone tumours varies depending on the type. However, they most commonly
arise in people less than 30 years old, often triggered by the hormones that stimulate normal growth.
The most common type is osteochondroma.
This review discusses the different types of common benign tumours of the bone based on
information accumulated from published literature.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Benign tumours of the bone consist of a wide variety of different
neoplasms. These tumours vary in terms of incidence, clinical pre-
sentation and require a diverse array of therapeutic options. The
incidence of benign bone tumours is debated due to their often asym-
ptomatic presentation and difﬁculty in detection [1]. Overall, 8 differ-
ent types can be distinguished; osteochondroma, osteoma,
osteoid osteoma, osteoblastoma, giant cell tumour, aneurysmal bone
cyst, ﬁbrous dysplasia and enchondroma. These tumours can be roug-
hly divided into categories based on their cell type: bone-forming,
cartilage-forming, as well as connective tissue and vascular [2]. Some
other forms of benign tumours may also present, however due to their
low incidence they will not be discussed. We will discuss the most
common ﬁrst followed by descending prevalence.
2. Osteochondroma
These cartilaginous tumours represent most of the benign bone
tumours (approx. 30%). Most commonly found in the femur and tibia,
osteochondroma occur mainly in the metaphysis and diametaphysis
and projects out of the underlying bone. The cartilaginous cap is the
site of growth, which normally diminishes after skeletal maturity.
Whilst solitary osteochondroma (exostosis) is normally encountered
within the ﬁrst four decades [3], the hereditary and autosomal form
predominantly occurs at a younger age and may present with limb
shortening and deformity.
Conventional radiology (using anatomical location, transitional
zone and mineralisation of matrix) is used to diagnose chondroid
tumours[4]. When there is no mineralisation of the cortex, diagnosis
becomes more difﬁcult and Computer Tomography (CT) or Magnetic
Resonance Imaging (MRI) may be used. MRI provides excellent dem-
onstration of arterial and venous compromise [5]. The most common
characteristics include: endosteal scalloping, thick periosteal reaction
and cortical hook. Only symptoms caused by the tumour warrant
surgical removal and can provide excellent results [6].
Conventional radiology (using anatomical location, transitional
zone and mineralisation of matrix) is used to diagnose chondroid
tumours. If there is no evidence for mineralisation of the cortex,
diagnosis becomes more difﬁcult and Computer Tomography (CT) or
Magnetic Resonance Imaging (MRI) may be used. The most common
characteristics include: endosteal scalloping, thick periosteal reaction
and cortical hook. Surgical removal of the tumour normally produces
an excellent clinical result.
3. Giant cell tumour of bone
Twenty per cent of all benign bone tumours are giant cell
tumours (GCT), and mostly appear between the ages of 20 and 40
[7,8]. The location of GCTs can vary – most occur in the long bones,
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predominantly in the area of the knee (50–65%). Histologically,
GCTs consist of giant cells with osteoclast like function surrounded
by spindle-like stromal cells and other monocytic cells [7,9]. GCTs
are usually benign (80%). However, recurrence after excision may
occur in 20–50%, with 10% becoming malignant on recurrence [10].
GCTs appear on plain radiographs with the appearance of a lytic
cystic lesion, with well deﬁned, non-sclerotic margins [7,10]. These are
usually located in the epiphysis of bones, with eccentric growth
patterns. Other common features include cortical thinning, expansile
remodelling of the bone, and prominent trabeculation [9]. In aggres-
sive tumours radiographs may demonstrate cortical thinning, cortical
bone destruction, and awide zone of transition [9]. Pathologic fracture
is a feature in between 11% and 37% of patients. [9,11]
Although GCTs are usually diagnosed on the basis of radiographic
evidence, a number of additional imaging tools may help to con-
ﬁrm the diagnosis. In 57% of cases ‘donut sign’ is present on bone
scintigraphy, a result of increased peripheral uptake of radionuclide
[12].
The use of CT imaging is helpful in examining the extent of the
tumour margins. CT is superior to radiographic imaging in the
recognition of certain features of GCTs, including cortical alterations
and periosteal reactions [9]. MR imaging is the most accurate tool for
demonstrating GCTs margins [9,13]. However, it is less effective than
CT imaging at demonstrating changes in the cortex of the bone [13].
Functional imaging tools such ﬂuoro-2-deoxy-D-glucose positron
emission tomography have been identiﬁed as a potentially useful tool
in identifying malignancy in musculoskeletal tumours [14]. There has
been less research into the usage of PET in identifying benign bone
tumours [15]. There is some evidence demonstrating that in PET giant
cell tumours and other tumours containing giant cells display high
FDG uptake [15–17]. It has been suggested that FDG PET may there-
fore be useful in the imaging of giant cell tumours after recurrence,
where normal anatomy may be distorted [18].
Primarily, the management of GCTs has been curettage followed by
ﬁlling with bone cement [7,19]. However this has been associated
with high recurrence rates. Additional treatment with adjuvants is
often employed to reduce this recurrence. These adjuvants may
include zinc chloride, bisphosphonates, phenol, liquid nitrogen and
alcohol. [20–23]. Aggressive tumours may also be treated with wider
excision and the use of surgical prostheses [9].
A recent development in treatment has been the use of the
chemotherapy drug, denosumab, a monoclonal antibody which
inhibits the osteoclastic activity of GCT [7]. This is useful when the
location of the tumour makes surgery difﬁcult, for example in the
sacrum or pelvis [7]. Interim results of a phase II trial have shown
that the drug may be used to reduce the need for more extensive
surgery in difﬁcult to resect tumours [24].
4. Osteoblastoma
Osteoblastoma is a rare, benign bone tumour accounting for 14% of
bone tumours [25]. It most commonly affects people within the ﬁrst
four decades of life with a larger probability of it occurring in the
second and third decades [26]. Although any bone can be involved,
osteoblastoma arises predominantly in the axial skeleton with spinal
lesions constituting one-third of reported cases [27]. On CT imaging,
osteoblastoma appearance is changeable and can often look like other
tumours, including malignant ones. They can be distinguished due to
their signiﬁcantly large nidus size (42 cm in diameter, sometimes up
to 15 cm) compared to osteoid osteoma [28], but diagnosis needs to
be conﬁrmed on biopsy. Their nidus is formed by dense sclerotic
woven bone and tumour trabeculae frequently connect with the
surrounding bone. Osteoblastoma tends to remain conﬁned to bone
and does not normally penetrate the cortex, it has therefore usually a
good prognosis and a low recurrence rate of around 15–20% [29]. The
ﬁrst line of treatment is medical [30], if proven unsuccessful radio-
therapy and chemotherapy might be attempted before choosing
surgical interventions. There have only been a few cases reported
where osteoblastoma has progressed to an osteosarcoma [31].
5. Osteoma
Osteomas are a benign outgrowth of membranous bones, most
commonly found in the para-nasal sinuses, skull and long bones [32].
These benign tumours can grow on bone (homoplastic) and can
present on other tissues (heteroplastic or eteroplastic) [33]. They
consist of osseous tissue that comprises of condensed bone with a
well-deﬁned border, without surface irregularities or satellite lesions.
Without symptoms they are difﬁcult to diagnose. Because of their
increased incidence in divers and swimmers an inﬂammatory
response has been thought to be one of the underlying mechanisms
[34]. Solitary osteoma are usually harmless, however if multiple are
found they are a risk that the patient may have other underlying
conditions, such as Gardner's syndrome [35]. Although rare, surgical
removal is indicated in these circumstances as well as in symptomatic
patients.
6. Osteoid osteoma
Rarely exceeding 1.5 cm, osteoid osteoma is a benign bone tumour
composed of osteoid and woven bone. Osteoid osteomamakes up 12%
of all skeletal neoplasms, making it quite common. 50% of osteoid
osteoma lesions are found in the ﬁbia or tibia. The cortex of long
bones is the most common location of the lesion. Dense, fusiform,
reactive sclerosis characterise osteoid osteoma [36]. It is more
commonly found in young males under the age of 40 [37], whilst
infants are rarely affected. The most common symptom is pain. The
axial skeleton is affected much less, with skull and facial bones rarely
affected. MRI, CT scanning and Isotopic scanning may be used for
diagnoses and for the identiﬁcation of central calciﬁcations sur-
rounded by the nidus (ovoid translucency) [26]. In a study done by
Assoun et al. 19 patients were examined using CT and MRI, results
showed that CT was more accurate than MR imaging in detection of
the osteoid osteoma nidus in 63% of cases [38].
The osteoid and woven bone can be seen as interconnected
trabeculae (thin or broad) or sheets. The bone surrounding the lesion
(host bone) is strong and is made of varying mixtures of woven and
lamellar bone [36]. The radiologic appearance of cortical osteoid
osteoma arising in the shaft of a long bone has certain characteristics.
It may be radiolucent and contain a changeable amount of mineralis-
ation and is usually centrally positioned in an area of reactive oste-
osclerosis (dense fusiform, reactive). Sclerosis may regress after
surgical removal of the tumour. Preoperative administration of tetra-
cycline and the use of UV light for examination during the procedure
may enhance the surgeon's view of the nidus. This technique works
due to the tetracycline's position in the rapidly metabolised osteoid of
the nidus in contrast to the slow mineralising host bone [36].
Out of 860 cases reviewed by Jackson et al. only 1.6% found it
painless [39]. Most patients present with a swelling, mass or
deformity. Swelling may be associated with superﬁcial lesions.
Table shows the anatomical locations of the osteoid osteomas
and their characteristics:
Morphological and anatomical
location of Osteoid osteoma
[40]
Characteristics
Intracortical Dense sclerosis around the
nidus
Periosteal Periosteal reaction
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Spongiosal Produces very little reactive
bone
Subarticular Simulates arthritis as it
produces synovial reactions
7. Aneurysmal bone cyst
Aneurysmal bone cysts (ABCs) are fairly rare benign cystic lesions,
accounting for approximately 9.1% of all bone tumours [41]. The blood
ﬁlled cysts are divided by connective tissue septa and contain a mix of
osteoclasts, giant cells, and reactive woven bone [42–44]. Controversy
exists as to the pathogenesis of aneurysmal bone cysts. In 30% of cases
a predisposing lesion can be identiﬁed, a ﬁnding that some argue
suggests that aneurysmal bone cysts are a reactive process to other
pathological changes, rather than a distinct tumour type [42,44]. The
most common pre-existing lesion is the giant cell tumour [44]. The
sites most commonly associated with ABC are the femur, tibia, hum-
erus and ﬁbula, although they can present in other sites [42].
ABC appears on radiographs as radiolucent lesions of eccentric
origin in the metaphysis of long bones [42]. The term ‘soap bubble’
is used to describe these lesions, a description which describes the
erosion of the cortex of the bone and elevation of the periosteum
[43]. CT imaging can be helpful in identifying the margins of the
cyst [21]. MRI allows identiﬁcation of the thin septa dividing the
cyst, as well as demonstrating ﬂuid-ﬂuid levels within the cyst
[42]. Biopsy and histological examination of the ABC is necessary
to conﬁrm the diagnosis [41,42].
There are a number of management options for ABCs. Curettage
with bone grafting or resection and reconstruction for eccentric les-
ions has traditionally been used [43]. Curettage often involves adju-
vant therapy to reduce the recurrence rate, which may be as high as
31% [41]. This may involve sclerotherapy [45] or cryotherapy, which
has been shown to reduce the recurrence rate to 5% [46]. Embolization
procedures, namely the injection of alcohol zein or selective arterial
embolization, are highly controversial [41].
A number of novel potential treatments for ABC have recently been
described in case studies. These treatments are less invasive and thus
may offer an advantage over aggressive surgical options. The use of
Denosumab as a therapeutic agent for the treatment of ABCs has been
described in a study involving two patients with ABCs at C5, who both
displayed tumour regression at 2 or 4 months [47]. However, more
research in this area is required. New graft material such as autologous
bone marrow mononuclear cells combined with B -tricalcium phos-
phate and atelocollagen has also resulted in ossiﬁcation of the cyst in
one patient [48]. These case studies show potential for resulting in
innovative treatments for ABC, however more extensive trials are
necessary before ﬁrm conclusions can be drawn.
8. Fibrous dysplasia
Fibrous dysplasia (FD) accounts for 5–7% of all benign bone
tumours [49]. Fibrous dysplasia presents in two main forms –
monostotic, affecting one bone, or polyostotic, which affects several
bones. 75% of cases of ﬁbrous dysplasia are of the monostotic form
[50]. Monostotic ﬁbrous dysplasia typically affects those in their 3rd
decade of life, whist polyostotic presents in the 1st decade [51].
Polyostotic FD commonly affects the craniofacial bones, but may also
affect the ribs, femur or tibia [51]. Fibrous dysplasia consists of ﬁbrous
stroma with a cellular component, with mutated ﬁbroblast cells
and osteoblasts of varying functionality, which produce abnormally
shaped trabeculae of woven bone [51,52]. FD mostly becomes
dormant as the affected child moves into adulthood, however there
is a lifetime risk of malignant transformation that of around 1–4% [53].
FD appears radiographically as radiolucent areas which later
develop into a partially opaque ground glass appearance [51]. Other
features that may be present are endosteal scalloping, bony expansion,
and a thick reactive bone ‘rind’ [54]. MR imaging may be a more
effective tool at identifying the size of the area affected by FD, and
could be useful when the radiographic appearance of suspected FD is
ambiguous [54].
FD is usually treated conservatively by maintenance bone density
with regular exercise and diet [50]. Medical therapy such as the use of
bisphosphonates, particularly pamidronate, may be effective at redu-
cing pain in FD, however there is a need for trials to provide further
evidence of this effect [55]. It has been suggested that other medical
therapies such as denosumab and pregabalin may be potentially
useful treatments at reducing pain from FD [55]. Currently little
evidence exists to support these hypotheses.
Surgery is considered in patients with progressive symptoms or
when the disease threatens important anatomical structures [51].
Treatment is often curettage followed by autologous bone graft. Cor-
tical bone grafts are deemed superior to cancellous bone grafts, by
virtue of their ability to resist replacement by the FD lesion [49].
Where FD has resulted in deformity, corrective surgery may be
required, for example osteotomy and intramedullary ﬁxation [49,53].
Recurrence occurs in around 18% of cases [56].
9. Enchondroma
Only 2.6% of all benign bone tumours can be considered an
enchondroma [52]. These asymptomatic tumours may present at
any age, however 59% occur between the ages of 10 and 39 [52].
These tumours consist of masses of hyaline cartilage in a lobular
formation, typically presenting in long tubular bones, most commonly
the hands and feet [52,57]. These are usually solitary lesions, but it is
possible for multiple enchondromas to form, a condition that is
described as enchondromatosis or Ollier's disease [58].
During diagnosis it is essential to distinguish between a benign
enchondroma and low grade chondrosarcoma. Enchondroma occurs
more frequently in the hands and feet and chondrosarcoma in the
axial skeleton – however accurate diagnosis is necessary given the
different treatment routes required for both lesions [59]. Radiographic
features of enchondromas include stippled calciﬁcation, endosteal
scalloping, with areas of ossiﬁcation or expanded cortex [52,57]. MRI
allows identiﬁcation of classic features of malignancy such as cortical
destruction, soft tissue masses, multilocular appearance, and involve-
ment of ﬂat bone [60]. Cartilaginous islands surrounded by fat may
also be a potentially useful diagnostic sign detected on MRI scans [61].
Enchondromas do not routinely require surgical treatment, unless
they are symptomatic, increasing in size, or there is a risk of path-
ological fracture. Typically treatment of enchondromas has involved
intralesional excision, followed by ﬁlling with an autologous bone
graft or synthetic ﬁlling [57]. Adjuvant treatments have been used to
reduce recurrence rates, however this is not normally necessary as 10
year recurrence is around 0.04% [57,62]. In recent years trials have
suggested that curettage without augmentation or reconstruction is a
potential new treatment [63]. This evidence suggests that the time for
the formation of new bone is similar in groups of patients whether
they receive grafts or undergo simple curettage [64]. A recent case
series has suggested that a lateral approach during tumour excision,
as opposed to the traditional dorsal approach may help to reduce
postoperative stiffness [65].
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Summary table
Type Incidence (% of
all benign bone
tumours)
Diagnosis
Pathology
features
Treatment Recurrence
rates
Osteochondroma 35 Radiograph, CT
and MRI are
useful, but
biopsy is
necessary to
conﬁrm
diagnosis
Lesions
occurring in
metaphysis and
diametaphysis
and projects out
of the underlying
the bone
Surgery
necessary if
active or
aggressive
o2%
Giant cell
tumour
20 Radiograph. CT
or MR imaging
may be useful
Soft, grey or red
tumour often
with small blood
ﬁlled cysts
Necessary due to
the risk of
malignant
transformation
20–50%
Osteoblastoma 14 Conventional
radiology. MDCT
plays a major
role in
identifying
osseous matrix.
CT or MRI may
be helpful when
there is no
mineralisation of
the cortex
Aneurysmal
bone cyst may
superimpose and
may be
associated with
osteoblastoma.
In long bones,
periosteal
reaction may be
prominent
1st line: medical
followed by
controversial
radio/
chemotherapy or
surgical removal
9.8%
Osteoma 12.1 Radiograph, CT
and MRI are
useful, but
biopsy is
necessary to
conﬁrm
diagnosis
Tosseous tissue
that comprises of
condensed bone
with a well-
deﬁned border,
without surface
irregularities or
satellite lesions
Surgery
necessary if
active or
aggressive
N/A
Osteoid osteoma 10.8–13.5
Radiograph, CT
and MRI are
useful, but
biopsy is
necessary to
conﬁrm
diagnosis
Intracortical
osteoid osteoma
produces dense
sclerosis around
the nidus.
Subperiosteal
type produces
periosteal
reaction while
spongiosal type
produces very
little reactive
bone.
Surgery
necessary if
active or
aggressive
4.5%
Aneurysmal
bone cyst
9.1 Radiograph, CT
and MRI are
useful, but
biopsy is
necessary to
conﬁrm
diagnosis
Blood ﬁlled
cavernous spaces
with septa
Surgery
necessary if
active or
aggressive
31%
Fibrous dysplasia 5–7 Radiograph. CT
or MR imaging
may be useful
Dense ﬁbrous
tissue with
osteoid
trabeculae
Surgery
necessary if
chronic bone
pain consists
after medical
treatment, or if
complicated by
fractures
18%
Enchondroma 2.6 Radiograph, CT
and MRI.
Histologic
evaluation
necessary to
exclude
chondrosarcoma
Masses of
hyaline cartilage
in lobular
formation
Consider if
symptomatic or
at risk of fracture
0.04%
10. Conclusion
Benign bone tumours are a group of neoplasms that are most
frequent in children and young adults, although they may also present
in later stages of life. They are most often diagnosed on the basis of
radiographic evidence; however, CT and MRI imaging may be of some
use in deﬁning the extent of tumour spread locally. For the majority
treatment is only indicated in symptomatic patients or if there is risk
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of pathological fracture or deformity, with surgical intervention as
most deﬁnite treatment option. Active treatment is usually only
necessary in GTCs and aneurysmal bone cysts, due to their risk of
malignancy. However, for most of the benign bone tumours there is
no general consensus on standards of treatment, and the number of
different adjuvants utilised in surgical treatments means recurrence
rates vary widely.
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